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Introduction  
Clostridium, especially Clostridium botulinum, produce 
botulinum toxin A (BtxA). BtxA is the strongest biological 
neurotoxin known to human beings.1 Many studies showed 
that subcutaneous injection of BtxA into the muscle 
leads to flaccid paralysis via blocking the neuromuscular 
junction.2 Therefore, this neurotoxin has widely used 
to relieve neurological symptoms such as muscle spasm 
and reduce pain and motor disorders. In recent years, 
therapeutic and experimental evidence emerged about 
the mechanisms of the BtxA as a neurotoxin. It has shown 
that BtxA not only affects the peripheral nervous system 
but also affect the central nervous system too. In fact, 
the toxins are produced as pro-toxins and activated by 
proteolytic cleavage into disulfide bond-linked chains 
consisting of 100-kDa heavy chain (HC) and 50-kDa 
light chain (LC). The HC of BtxA neurotoxin binds to the 
presynaptic receptors exposed during vesicle recycling. 
The terminal carboxyl of Hc binds to specific gangliosides 
and proteins associated with the vesicle membrane (Syt 
and SV2 isoforms).3
In addition to inhibiting nerve cells, BtxA is capable of 
inducing apoptosis in many cancerous cells.  For example, 
ovarian cancers are among the most common female 
genital tract cancers, and it has the worst prognosis, and 
it is currently in the 7th grade of mortality.4,5 Breast and 
prostate cancers are the most common cancers after lung 
cancer. The incidence of breast cancer accounts for about 
one-third of all cancers in women with an increasing 
trend among Iranian women. Concerning increased 
age and population in Iran, the rate of cancer cases has 
expected to increase in the coming years.6 Breast cancer is 
a heterogeneous disease in gene expression, morphology, 
clinical course, and response to treatment. Common 
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breast cancer treatments include surgery, chemotherapy, 
radiotherapy, hormone therapy, or targeted therapy.6
On the other hand, prostate cancer is also the second 
leading cause of death in men worldwide and the 
eighth cause of cancer death in Iran. However, the 
most commonly applied prostate cancer treatments are 
radical prostatectomy, external radiation therapy, and 
brachytherapy.7,8 Despite many efforts that have put in the 
treatment of these mentioned cancers, their mortality rate 
remains high. According to the literature, the interest in 
using BtxA for some type of cancer has increased. Several 
studies conducted on the therapeutic effects of BtxA, anti-
cancer effects of which have been evaluated in vivo and 
in vitro. 
Coarfa et al demonstrate that nerves play a role in the 
homeostasis of normal epithelial tissues and are involved 
in prostate cancer tumor survival. They emphasized that 
the cross-talk between cancerous cells and the neural 
microenvironment surrounding them play an important 
role in disease progression and may make a significant 
impact in general cancer treatment strategies, as nerve/
cancer interactions are likely important in other cancers as 
well. Targeting neural microenvironment may represent a 
therapeutic approach to treating human prostate cancer.9 
In vitro and in vivo induction of apoptosis of the human 
prostate cancer LNCaP and PC-3 cell lines by BtxA in a 
dose-dependent manner reported recently.10  Also, in 
2015 a study by Bandala et al on 3T3 cell lines showed 
that Botox’s effect in a dose-dependent manner inhibits 
growth and causes cell death.11 In 2012, Gorgal et al used 
BtxA as a new treatment for benign prostatic hyperplasia 
to examine apoptosis regulatory proteins’ expression in 
the rat prostate after the injection of this compound.12 
Gabriel et al, in 2015, studied the role of BtxA in post-
mastectomy breast reconstruction and suggested the 
antinociceptive effects of BtxA and its potential benefits in 
reducing postoperative pain.13 The hypoxia of the tumors 
is well known as a response to radiation since adequate 
perfusion is necessary to deliver chemotherapy drugs. 
Therefore, radiotherapy and chemotherapy that cause 
transient oxygenation can be used just before cytotoxic 
therapy.14
It had known that radiotherapy and chemotherapy 
cause complications, such as spastic contraction and 
painful muscle spasms. BtxA is not only used to treat 
symptoms associated with cancer itself but also to treat 
the complications following chemotherapy or radiation 
therapy. Several studies have shown that BtxA, in addition 
to its effects on blood supply and neurotransmitters, 
causes cell death in many cell lines.10,11,15
To our knowledge, the effects of BtxA, as a well-known 
neurotoxin on PC-3 prostate, MCF-7 breast cancer, SK-
OV3, and CHO ovarian cell lines had not studied yet. The 
present study has designed to find the possible apoptotic 
effects of BtxA on these cancer cell lines.
Materials and Methods 
The present research is an applied experimental cellular 
and molecular study. 
Reagent and Chemical
SK-OV-3, CHO, MCF-7, and PC-3 cell lines had purchased 
from the Iran pasture institute. RPMI-1640 (Gibco) and 
DMEM (Sigma) were purchased. BtxA (Canitox, China) 
and Annexin V & PI kit also purchased from Sigma. The 
antibody of  Caspase 3 (Abcam) was purchase.
BtxA Preparation 
In this research, BtxA purchased from Canitox, China. 
Each vial, containing 100 U (4.8 ng) solvent in sterile 
saline 9% and different concentration (1.35, 1.45, 1.65, 
1.75, 2.25, 2.40, 2.50), was prepared and used in below 
one hour. 
Cell Culture
The cells were cultured in RPMI-1640 medium culture, 
10% FBS (Gibco), 1% L glutamine, and 1% pen/strep. 
Afterward, the cells incubated at 37˚C, 5% CO2, and 96% 
humidity, followed by their sub-culturing with Trypsin/
EDTA (Sigma). After three subcultures, the obtained 
product had used for the tests.
Viability Assay
Cellular metabolic activity evaluated by MTT assay, 2×104 
cells were transferred into flat 96-well plates and incubated 
at 37°C in a humidified air atmosphere enriched with 
5% (v/v) CO2 for 24 hours to allow the cells attach to 
the bottom of each well. Botox’s various concentrations 
were treated for all cell lines in triplicate for 24, 48, and 72 
hours, respectively. At the end of the treatment, the culture 
medium was replaced with fresh medium and added to 20 
μL of MTT (5 mg/ml in PBS) for four hours. Formosan 
crystals were formed by mitochondrial reduction of MTT 
in living cells only and solubilized in DMSO (200μL/well). 
Their absorbance was read at 570 nm after 10 minutes of 
incubation by an ELISA reader (Bio-Rad, USA).
 
Annexin V/PI Staining
The test performed in removable eight-chamber slides 
(Lab-Tek, Nunc) with 5000 cells/well in triplicate 
(12ml/well). The cells have incubated at 37°C for 24, 
48, and 72 hours. Following that, the cells were fixed in 
methanol-acetone (V/V) for 10 minutes at 20°C and were 
then incubated with 10 ml Annexin V-FITC (Bender 
MedSystems, Souffelweyersheim, France) in HEPES 
buffer (10 mm HEPES/NaOH, 150 mm NaCl, 5 mm 
KCl, 1 mm MgCl2, 1.8 mm CaCl2, all reagents from 
Sigma) for 15 minutes at 37°C. They were incubated 
with PI at 20 mg/ml in the HEPES buffer for 10 minutes 
at room temperature in the next stage. The cells have 
then visualized using an Olympus microscope at 400× 
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magnification using 490-nm and 580-nm emission filters 
to visualize the green FITC fluorescence and detect the 
red PI staining, respectively. 
PI Staining 
propidium iodide (PI) staining had used to identify the late 
stage of apoptosis. One million cells per sample fixed in 1 
mL cold ethanol 70% were added (dropwise) to cell pellet 
and vortexes (fixed for at least 30 minutes on ice). Ethanol-
fixed cells were centrifuged, and to ensure that only DNA 
was stained, the cells treated with 50 μL Ribonuclease A. 
Also, 450 μL propidium iodide per one million cells was 
added directly to cells in RNase A solution. The sample 
was then incubated for 10-15 minutes and was analyzed 
by flow cytometry in PI/RNase A.
Blotting Assay
Western blot analysis has performed as described 
previously.16 Proteins measure with the Bio-Rad protein 
assay method. Equal amounts of protein were loaded 
and separated by SDS-poly acrylamide gel (12%) for 
electrophoresis and transferred to polyvinylidene fluoride 
membranes. The protein was extracted from the cell 
and placed on the SDS-PAGE gel. The SDS PAGE gel 
used to purify proteins of the cells. The protein was 
separated on the gel-protein samples and transferred 
to the polyvinylidene difluoride (PVDF) membrane, 
and eventually, protein samples, which revealed on the 
PVDF membrane, were detected using the ECL kit. After 
blocking with buffer containing 3% of ECL Advance in 
PBS/Tween 0.3% for 1.5 hours at room temperature, the 
membrane probed with specific polyclonal antibodies 
(Abcam) diluted in blocking solution (Caspase3 1:7500, 
P53 1:7500) antibodies were added to the membrane 1 
hour at room temperature. Then, a secondary antibody 
added onto the membrane. After the incubation time, the 
secondary antibodies were removed and washed by a tris-
buffered saline (TBS) buffer for 3 to 10 minutes
Statistical Analysis
Data analysis was performed by SPSS version 21, with 
three replications. The mean ± SER experimental data 
were evaluated with one-way ANOVA and Duncan test. 
P < 0.05 was considered significant.
Results
The viability assay results in different concentrations, and 
time on MCF-7 cells showed decreases in the viability 
of treated BtxA cells at 1.45U doses with the 65.45% cell 
viability after 24 hours. Data showed a significant decrease 
in live-cell in all doses at 24 and 48 hours compared to the 
control group (P < 0.001). CHO viability results showed 
a significant decrease between BtxA treated cells and the 
control group in 24 hours (P < 0.001). The Cell viability 
percentage was dose-dependent, and the effective 
concentration in a CHO cell line was 1.65 U with 56.03% 
cell death. Also, in SKOV3 BtxA treated, at 1.75 U caused 
59.22% cytotoxicity after 24 hours; this finding was dose-
dependent for both cell lines (Figure 1). The  PC-3 cell 
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Figure 1. Comparison of Viability Percentage of MCF-7 Cells at 
Different Times. 
Cell viability and mean ± SER percentage between the control 
group and the concentrations in CHO and SK-OV-3 cell lines 
after 24 and 48 hours *(P < 0.05). ‡ (P < 0.05) with 72 hours at the 
same dosage.
Table 1. The Mean Percentage of Viability of PC3 Cells Between Different Concentrations and Times in All Groups
Botox group Control 1.45 U 1.75 U 2.25 U 2.40 U 2.50 U 4.50 U
Live cell% 24h 95.65±87.8 89.32±23.4 80.87±24.8 90.35±56.6 93.21±58.7 80.75±24.4 83.56±88.9
Live cell % 48h 93.75±35.3 89.22±93.4 88.76±32.4 91.00±98.7 95.45±33.1 88.84±22.5 83.76±54.8
Live cell% 72h 96.42±66.8 93.35±44.5 90.72±13.5 88.80±29.5 86.76±33.5 79.84±54.6 79.65±43.6
MCF7
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Figure 2. Comparison Necrosis Peak Between Control and BtxA 
Treated Groups by PI Staining in MCF7, SKOV3, and CHO Cell 
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Figure 3. Represented Annexin V & PI Assay Results in PC-3 (A) and MCF-7 (B), SK-OV-3 (C), 
and CHO (D) BtxA and Control-Treated Cell Lines  Groups After 24 Hours Comparison Apoptosis 
Peak in AnnexinV /PI test  
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Figure 3. Represented Annexin V & PI Assay Results in PC-3 (A) 
and MCF-7 (B), SK-OV-3 (C), and CHO (D) BtxA and Control-
Treated Cell Lines  Groups After 24 Hours Comparison Apoptosis 
Peak in AnnexinV /PI test 
different concentrations up to 4.50U doses and time, and 
these cells were resistant to the BtxA (Table 1).  
The results of  PI staining for evaluating the DNA 
content of all cell lines have shown in Figure 2. Data from 
all BtxA doses showed a higher presence of necrotic cells 
after 24 hours. For the MCF-7 cells, 2.50 U of BtxA showed 
cell death more than 50%, and a significant difference 
between 2.50 U and other doses within 24 hours observed. 
In the CHO and SKOV-3 cells, the percentage of necrosis 
at 1.75U was 59.22% and 72.84%, respectively, after 24 
hours, which showed a significant difference compared to 
the control groups (P < 0.001) in 24 hours.
The results of Annexin V & PI assay revealed that in 
MCF-7 cells, significant apoptosis and proliferation 
inhibitory effect induced within 24 hours. Also, at the 
2.50 U of BtxA, late and early apoptosis was 14.16% and 
45.45%, respectively, whereas necrosis observes in the 
PC-3 cell line instead of apoptosis (Figures 3A & 3B). 
In two other cell lines, results showed the percentage of 
annexin V- positive cells increased. In CHO cells at the 
1.45, 1.65, and 1.75 units and SKOV-3 at the 1.65, 1.75, 
and 1.85 units of BtxA, significant apoptosis percentage 
were observed (P < 0.001) (Figure 3C & 3D). Comparison 
apoptosis percentage between different concentrations 
treated cells and control after 24 and 48 hours in 3 cell 
lines shown in Figure 4.
Blotting assay results showed increases in the expression 
of Caspase 3 in treated BtxA group compared to the 
control group in all cell lines except PC-3 cells after 24 
hours (Figure 5).
Discussion
Cancer is one of the most important health problems in the 
world, and many researchers have put effort into finding a 
treatment with minimal side effects and the most efficient 
results. Breast and prostate cancers are the eighth leading 
causes of death in Iran. There are different treatments for 
them, including chemotherapy, radiation therapy, and 
hormone replacement therapy. While these therapies are 
available for the mentioned cancers, they are associated 
with several complications. BtxA, as a neurotoxin, is used 











Figure 2. Comparison Necrosis Peak Between Control and BtxA Treated Groups by PI Staining 
in MCF7, SKOV3, and CHO Cell Lines After 24 Hours. 
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is being used today as medicine and treatment of cancer. 
Using medicines such as doxorubicin, daunorubicin, 
bleomycin, and cisplatin is a routine cancer treatment 
procedure. Nevertheless, they are costly and accompanied 
by complications, such as bone marrow suppression, 
anemia, and, most importantly, increased cellular 
resistance. Therefore, alternative therapies or drugs must 
be found to overcome these problems.
Ansiaux et al, in 2007, reported that BtxA could use as 
adjuvant therapy for cancer. In their study also no direct 
cytotoxic effect was observed when BtxA was incubated 
directly with tumor cells; therefore, it is unlikely that the 
inhibition of cell division by BtxA will be enough power 
to be used alone to treat cancer. They suggested that the 
benefit from BtxA was directly related to a change in the 
tumor neuronal microenvironment and not to a direct 
cytotoxic or radiosensitizing effect.17 In 2013 Bandala et 
al conducted a study to assess the effect of BtxA apoptotic 
on T47D breast cancer cells and estimated the effect of 
0.15 U of BtxA on survival and cell death using MTT and 
propidium iodide/annexin-V.11 BtxA caused a greater 
cytotoxic activity in T47D cells than normal MCF10A 
cells, which seemed to induce caspase-3 and -7 dependent 
apoptotic processes. The toxicity and apoptosis of BtxA 
in their study led us to investigate the effect of BtxA 
on another type of cancer cells. In the present study, 
we showed BtxA capable of reducing cell viability in a 
dose-dependent manner and induced apoptosis in three 
different cancer cell lines. Also, the annexin V/PI results 
by using flow cytometry confirmed the Botox apoptosis 
induction. Similar to the results of Bandala et al, our 
findings demonstrated that those 24 hours were effective 
inducing apoptosis, and it seems that the MCF-7 cell line 
had a similar mechanism for responding to BtxA but with 
the different doses. According to the Bandala et al report, 
BtxA did not affect the normal MCF10A cell line despite 
our study for SKOV-3 and CHO cell lines. Our findings 
showed the dose and time-dependent effects of BtxA 
on both different types of cells. Karsenty et al, in 2009, 
suggested that intraprostatic injection of BtxA improved 
urinary symptoms associated with benign prostatic 
hypertrophy (BPH). They showed cell proliferation of 
PC-3 and LNCaP cell lines compared to the presence and 
absence of BtxA after four days. Also, the BtxA membrane 
receptor synaptic protein vesicles 2 (SV2) studied in 
both cell lines. The results showed that BtxA, in a dose-
dependent manner, significantly reduced LNCaP cell 
proliferation and increased apoptosis. However, there 
was no effect showed on the PC-3 cell line. The SV2 
receptor in both cell lines (LNCaP/PC-3) allows the BtxA 
to penetrate the cell and block cell proliferation factor, 
so inhibited the growth of human PSA and LNCaP cells 
in vitro and in vivo.10 In the present study, BtxA did not 
affect the PC-3 cell line at all concentrations and times, 
even to 72 hours. According to Karsenty et al, PC-3 cells 
have a lesser SV2 receptor than other types of prostate 
cancer. Flow cytometry showed significantly increased 
apoptosis in both cell lines with different doses (SK-OV-3 
with 1.75U and CHO with 1.65U) in a shorter time.10  The 
western blotting results confirmed the apoptotic effects 
of BtxA with the overexpression of caspase 3. Although 
BtxA approved to be useful to induce apoptosis for some 
types of cancer cell lines either in vivo or in vitro research, 
it has not exactly known why it has no or fewer effects on 
some other cell line. More research needs to explain the 
molecular mechanisms for the BtxA effects.
Conclusion
BtxA, first known for its neurotoxicity on neuromuscular 
Figure 4. MCF- 7, CHO, and SKOV-3 Cells Apoptosis Percent on 
AnnexinV/PI Test. Mean ± SER. * Significant difference with the 
same dose *P < 0.05. 
Figure 5. Comparison of the Expression of Caspase 3 in All Cell 
Lines Between Control and Treated BtxA Groups.
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junctions, could be supposed as a neurotoxin that acts as 
an apoptotic inducer with therapeutic effects on cancer 
cell lines. Although the action mechanisms of BtxA are 
not exactly known, we believe it may act via the neuronal 
niche around the tumoral cell. More research needs for 
a better understanding of BtxA mechanisms on cancer 
cells. 
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